Delve into the hidden innovation system of drug repurposing. When patents expire and commercial value fades, a new wave of ...
The premise is straightforward — we are awash in biological data. The rapid growth of multiomics datasets (genomics, transcriptomics, proteomics, metabolomics, and radiomics) together with ...
Miles Wang, an OpenAI researcher, is in talks to raise $200M at a $2bn valuation for an AI drug-discovery startup that has no name or product yet.
The Mathematical Cybernetics Laboratory focuses on drug repurposing. The application of computational methods, including AI, is supposed to determine whether existing drugs already on the market and ...
Through predictive modelling, AI supports target identification, prediction of physicochemical properties and formulation strategy selection.
Google DeepMind’s Coscientist and Future House’s Robin use multi-agent AI systems to propose testable biomedical hypotheses ...
CSIR-IICT scientists have used AI-driven structural bioinformatics to identify a promising repurposed drug candidate against poxviruses, including Mpox and Lumpy Skin Disease Virus.
Modern biopharma firms are adapting their R&D investment strategies in response to challenges such as the impending $300 ...
AI is no longer just for coding or drug discovery. Companies like L'Oréal, Mondelez, Nestlé and Haleon are using it to create ...
What if the cure for your disease was already sitting on a drugstore shelf? That's the audacious premise driving Dr. David ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results